Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Stryker Corporation (SYK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Stryker Corporation — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.78 (market cap $4.49B), while Stryker Corporation trades at $329.56 (market cap $126.41B). The key difference: Stryker Corporation is far larger — about 28.2× ACADIA Pharmaceuticals Inc.'s market cap, and Stryker Corporation pays a 1.07% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | SYK | |
|---|---|---|
Market Cap | $4.49B | $126.41B |
Sector | Health | Technology |
52-Week High | $28.06 | $403.53 |
52-Week Low | $20.06 | $282.58 |
Enterprise Value | $3.69B | $138.17B |
Dividend Yield | — | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Stryker (SYK) trades at $324.73, down 0.55% on the day, with a bullish technical outlook supported by moving averages. The company maintains strong fundamentals with 2025 revenue of $25.12B, net income of $3.25B, and consistent earnings beats in recent quarters despite a Q1 2026 miss. Analyst consensus remains strongly positive with 72% buy ratings and a $385.30 price target, representing 19% upside potential. Recent developments include new product launches and a strategic acquisition of Amplitude Vascular Systems.
SYK presents a compelling investment case with robust profitability (63.83% gross margin, 15.2% ROE) and strong institutional support. Key risks include cybersecurity incidents impacting operations and premium valuation metrics (P/E 37.58). The stock's current position near pivot point support at $323 suggests potential for recovery toward resistance at $329, supported by positive technical indicators and strong analyst conviction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
